I’m on two boards but not Biotech . The board h

I’m on two boards but not Biotech . The board has a duty to evaluate leadership based on results the Cd10 and cd12 trials in my mind , to be nice, have been mishandled. A continuation of finding 140 critically ill under 65 years old bodies is dwindling along with the concern in general about the company going it alone. Yes they can do warrants and it may grab some interest but the odds are stacked against Cytodyn going it alone. Ultimately Leronlimab needs to get to patients who will benefit from the drug and the shareholders need to get the value . I bought this company because of HIV and cancer and they need to thin out some of the spending on covid to focus those two other applications.
We probably disagree on most things but to me the long haulers is a better investment than the critically ill .and someone else at the helm who really understands the politics, relationships, and what is truly required to get across the finish line is needed .